Vertex Pharmaceuticals Incorporated
VRTX
$388.25
-$6.87-1.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.66% | -5.21% | |||
| Total Other Revenue | 107.00% | -- | |||
| Total Revenue | 7.02% | -4.87% | |||
| Cost of Revenue | -62.23% | 6.81% | |||
| Gross Profit | 72.16% | -13.74% | |||
| SG&A Expenses | 7.11% | 14.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.11% | 8.55% | |||
| Operating Income | 11.94% | -21.28% | |||
| Income Before Tax | 75.66% | -35.73% | |||
| Income Tax Expenses | 197.38% | -62.37% | |||
| Earnings from Continuing Operations | 59.82% | -29.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 59.82% | -29.21% | |||
| EBIT | 11.94% | -21.28% | |||
| EBITDA | 11.71% | -18.91% | |||
| EPS Basic | 59.94% | -29.04% | |||
| Normalized Basic EPS | 11.71% | -18.92% | |||
| EPS Diluted | 60.24% | -28.84% | |||
| Normalized Diluted EPS | 11.89% | -18.80% | |||
| Average Basic Shares Outstanding | -0.08% | -0.23% | |||
| Average Diluted Shares Outstanding | -0.23% | -0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||